Adial Pharmaceuticals Stock Price To Sales
| ADIL Stock | USD 1.45 0.25 20.83% |
Adial Pharmaceuticals fundamentals help investors to digest information that contributes to Adial Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Adial Stock. The fundamental analysis module provides a way to measure Adial Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adial Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 0.00 | 0.00 |
Adial | Price To Sales |
Adial Pharmaceuticals Company Price To Sales Analysis
Adial Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Adial Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Adial Pharmaceuticals is extremely important. It helps to project a fair market value of Adial Stock properly, considering its historical fundamentals such as Price To Sales. Since Adial Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adial Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adial Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Adial Pharmaceuticals has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Adial Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adial Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics of similar companies.Adial Pharmaceuticals is currently under evaluation in price to sales category among related companies.
Adial Fundamentals
| Return On Equity | -1.9 | ||||
| Return On Asset | -0.82 | ||||
| Current Valuation | 3.01 M | ||||
| Shares Outstanding | 4.23 M | ||||
| Shares Owned By Insiders | 4.03 % | ||||
| Shares Owned By Institutions | 7.75 % | ||||
| Number Of Shares Shorted | 132.32 K | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 2.31 X | ||||
| EBITDA | (6.89 M) | ||||
| Net Income | (7 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 207.38 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 2.46 X | ||||
| Cash Flow From Operations | (6.81 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (4.98) X | ||||
| Target Price | 17.0 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 6.14 M | ||||
| Total Asset | 4.74 M | ||||
| Retained Earnings | (68.8 M) | ||||
| Working Capital | 2.99 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
| Net Asset | 4.74 M |
About Adial Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adial Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Adial Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Adial Pharmaceuticals Piotroski F Score and Adial Pharmaceuticals Altman Z Score analysis. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Adial Stock analysis
When running Adial Pharmaceuticals' price analysis, check to measure Adial Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adial Pharmaceuticals is operating at the current time. Most of Adial Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Adial Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adial Pharmaceuticals' price. Additionally, you may evaluate how the addition of Adial Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Adial Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.98) | Return On Assets (0.82) | Return On Equity (1.90) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.